Patents Assigned to Genzyme Corporation
  • VEGF antagonist compositions and uses thereof
    Patent number: 9441029
    Abstract: The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 13, 2016
    Assignee: Genzyme Corporation
    Inventors: James Stefano, Clark Pan, Huawei Qiu, Michael O'Callaghan, Gloria Matthews
  • METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORS
    Publication number: 20160256534
    Abstract: Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.
    Type: Application
    Filed: March 25, 2016
    Publication date: September 8, 2016
    Applicants: Genzyme Corporation, The Regents of the University of California
    Inventors: Krystof Bankiewicz, Janet Cunningham
  • Gene therapy for neurodegenerative disorders
    Patent number: 9415119
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: August 16, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
  • Method of preparing oligomeric compounds using modified capping protocols
    Patent number: 9403865
    Abstract: Provided herein are methods for the solid phase synthesis of oligomeric compounds wherein at least one of the capping steps has been modified. More particularly, methods are provided wherein one or more of the capping steps is omitted or performed using reduced equivalents of acetic anhydride. In certain embodiments, the methods provide an enhanced purity profile. In certain embodiments, the methods provide an increased yield. The methods provided herein also provide at least an economic advantage over currently used methods in that reduced amounts of the mixture of capping reagents are required.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: August 2, 2016
    Assignees: Ionis Pharmaceuticals, Inc., Genzyme Corporation
    Inventors: Isaiah E. Cedillo, Darren Janczak, Phillip Michael Weaver
  • Administering antisense oligonucleotides complementary to human apolipoprotein B
    Patent number: 9347061
    Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: May 24, 2016
    Assignee: Genzyme Corporation
    Inventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
  • DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
    Publication number: 20160120957
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Application
    Filed: July 8, 2015
    Publication date: May 5, 2016
    Applicants: GENZYME CORPORATION, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF
    Publication number: 20160120958
    Abstract: The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 5, 2016
    Applicant: Genzyme Corporation
    Inventors: Wei-Lien CHUANG, Gerald F. COX, Kate X. ZHANG
  • Amine functional polyamides
    Patent number: 9326994
    Abstract: Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 3, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Pradeep Dhal, Kanwen Yang, Robert J. Miller, S Randall Holmes-Farley
  • Stepped cannula
    Patent number: 9302070
    Abstract: Described herein are cannulas having a stepped exterior. Also described are methods of making and using these cannulas, for example to deliver one or more materials to the central nervous system of an animal.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: April 5, 2016
    Assignees: Genzyme Corporation, The Regents of the University of California
    Inventors: Krystof Bankiewicz, Jurg M. Sommer
  • COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION
    Publication number: 20160083694
    Abstract: Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. ?˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.
    Type: Application
    Filed: May 1, 2015
    Publication date: March 24, 2016
    Applicant: Genzyme Corporation
    Inventors: John Fraser Wright, Guang Qu
  • COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
    Publication number: 20160074474
    Abstract: The present provides methods for treating spinal muscular atrophy using a self-complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administered the spinal column or cisterna magna in a human subject; for example, a pediatric human subject. Viral particles comprising AAV9 capsids are contemplated.
    Type: Application
    Filed: May 1, 2013
    Publication date: March 17, 2016
    Applicant: Genzyme Corporation
    Inventors: Marco A. PASSINI, Lamya S. SHIHABUDDIN, Catherine R. O'RIORDAN, Seng H. CHENG
  • Chemically modified dendrimers
    Patent number: 9283247
    Abstract: Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: March 15, 2016
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Robert J. Miller, Lauren Elizabeth Young, Rajesh Vasant Kamath
  • 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
    Patent number: 9272996
    Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: March 1, 2016
    Assignee: Genzyme Corporation
    Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Thomas H. Jozefiak, Frederic Vinick, Yibin Xiang, John Kane, Junkai Liao
  • PEPTIDE ANALOGS OF ALPHA-MELANOCYTE STIMULATING HORMONE
    Publication number: 20160046688
    Abstract: Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (?-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the ?-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.
    Type: Application
    Filed: August 19, 2015
    Publication date: February 18, 2016
    Applicant: GENZYME CORPORATION
    Inventors: Michael A. PERRICONE, John Lyle DZURIS, Timothy E. WEEDEN, James E. STEFANO, Clark Q. PAN, Andrea E. EDLING
  • SALT FORMS OF (S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE
    Publication number: 20160039805
    Abstract: The present invention relates to novel salt forms of (S)-Quinuclidin-3-yl(2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate useful as an inhibitor of glucosylceramide synthase (GCS) and for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Applicant: Genzyme Corporation
    Inventors: Craig S. SIEGEL, Jin ZHAO
  • AGENT FOR IMPROVING TISSUE PENETRATION
    Publication number: 20160031781
    Abstract: The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.
    Type: Application
    Filed: August 3, 2015
    Publication date: February 4, 2016
    Applicant: Genzyme Corporation
    Inventors: Hans-Jorg EIBL, Peter Hoffman
  • USE OF INOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
    Publication number: 20150353899
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Application
    Filed: January 7, 2014
    Publication date: December 10, 2015
    Applicant: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • TARGETING OF GLYCOPROTEIN THERAPEUTICS
    Publication number: 20150320844
    Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.
    Type: Application
    Filed: November 6, 2014
    Publication date: November 12, 2015
    Applicant: GENZYME CORPORATION
    Inventor: James Stefano
  • Tropomyosin-related kinase (Trk) inhibitors
    Patent number: 9174986
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: November 3, 2015
    Assignee: GENZYME CORPORATION
    Inventors: John L. Kane, Jr., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
  • Use polysaccharides for promotion of enzymatic activity
    Patent number: 9175283
    Abstract: This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid milieu, wherein the concentration of the polysaccharide in the composition comprising the Target Enzyme is from about 0.01% to about 55% w/v.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: November 3, 2015
    Assignee: Genzyme Corporation
    Inventors: Frank Riske, Michael Hayes, Gary Lazarus